title: Expression of the lactate transporter MCT1 in macrophages.
abstract: This study evaluated macrophage expression of the stereospecific lactate transporter, MCT1, and the effects of lipopolysaccharide (LPS), tumor necrosis factor (TNFa), or nitric oxide (NO) on MCT1 mRNA and protein levels and lactate transporter activity. Peritoneal and J774.1 macrophages were treated with either saline, LPS (10 or 100 ng/mL), dexamethasone (100 nM), and dexamethasone + LPS. Cells were harvested at 4, 8, and 16 h after treatment and processed for total RNA and protein isolation. LPS treatment significantly increased macrophage MCT1 mRNA expression at 4 and 8 h compared with the saline-treated cells. Dexamethasone did not alter MCT1 mRNA levels. Treatment of J774.1 macrophages with TNFalpha (1 ng/mL) or nitric oxide (DETA-NO, 100 microM) also significantly increased MCT1 mRNA levels at 4 and 8 h after treatment. LPS and TNFalpha treatment significantly increased MCT1 protein levels at 8 and 16 h after treatment. Lactate transporter activity in J774.1 macrophages was measured by uptake of 14C-labeled lactate. LPS and TNFalpha treatment significantly augmented lactate uptake, 12 h after administration; however, nitric oxide treatment did not affect lactate uptake. Thus, our data demonstrated that stimulated peritoneal and J774.1 macrophages express the lactate transporter, MCT, and that LPS and TNFalpha regulate MCT1 mRNA and protein levels.
authors.affiliation: Burn and Shock Trauma Institute, Department of Surgery, Loyola University Medical Center, Maywood, Illinois 60153, USA.
authors.forename: E L
authors.initials: EL
authors.lastname: Hahn
authors.forename: A P
authors.initials: AP
authors.lastname: Halestrap
authors.forename: R L
authors.initials: RL
authors.lastname: Gamelli
mesh_terms: D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D002460:Cell Line; D002478:Cells, Cultured; D003373:Coumaric Acids / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D007700:Kinetics; D007773:Lactates / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D027501:Monocarboxylic Acid Transporters; D020030:Nitric Oxide Donors / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D014158:Transcription, Genetic / Q000187:drug effects; D014226:Triazenes / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: C105351:1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene; D002352:Carrier Proteins; D003373:Coumaric Acids; D007773:Lactates; D008070:Lipopolysaccharides; D027501:Monocarboxylic Acid Transporters; D020030:Nitric Oxide Donors; D012333:RNA, Messenger; D014226:Triazenes; D014409:Tumor Necrosis Factor-alpha; C007175:alpha-cyano-4-hydroxycinnamate; D003907:Dexamethasone; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid